Stay updated on Johnson & Johnson Press Releases

Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Johnson & Johnson Press Releases page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    Important update:The change on the webpage represents the FDA approval of RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy as the first-line therapy for patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. This approval was based on positive results from the Phase 3 PAPILLON study, showing a significant reduction in disease progression or death compared to chemotherapy alone for this specific patient population.
    Difference
    12%
    Check dated 2024-03-02T03:26:34.000Z thumbnail image
  3. Check
    2 days ago
    Change Detected
    Summary
    Important update:The value on the webpage has changed from 900 to 901 on February 29, 2024, representing the announcement of CE Mark approval in Europe for the VARIPULSE™ Pulsed Field Ablation (PFA) Platform by Biosense Webster. This regulatory approval marks a significant milestone for the first fully integrated PFA system with a CARTO-enabled workflow for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF).
    Difference
    11%
    Check dated 2024-03-01T01:32:53.000Z thumbnail image
  4. Check
    3 days ago
    Change Detected
    Summary
    Important update:The value on the webpage has changed from 899 to 900 on February 27, 2024. This change represents Biosense Webster beginning the enrollment of a pivotal trial evaluating the Laminar Left Atrial Appendage Elimination Device, designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation.
    Difference
    5%
    Check dated 2024-02-29T00:46:45.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    Important update:The value on the webpage has changed from 898 to 899 on February 26, 2024, representing an announcement by Johnson & Johnson regarding the expansion of IMBRUVICA® label in the U.S. to include an oral suspension formulation for adult patients in its approved indications, providing additional flexibility for patients.
    Difference
    9%
    Check dated 2024-02-26T23:00:53.000Z thumbnail image
  7. Check
    9 days ago
    Change Detected
    Summary
    Important update:The recent change on the webpage from 897 to 898 represents an update in the news section. Specifically, it now features information about Janssen receiving a positive CHMP opinion for CARVYKTI® for the treatment of earlier lines of relapsed and refractory multiple myeloma, showcasing the potential benefits for patients in earlier stages of treatment.
    Difference
    8%
    Check dated 2024-02-23T22:26:03.000Z thumbnail image
  8. Check
    11 days ago
    Change Detected
    Summary
    Important update:The change on the webpage represents the approval by the U.S. FDA for biweekly dosing of TECVAYLI® (teclistamab-cqyv) for the treatment of patients with relapsed or refractory multiple myeloma. This approval provides patients with dosing flexibility and marks a significant development in the treatment options available for this condition.
    Difference
    9%
    Check dated 2024-02-21T21:29:22.000Z thumbnail image

Stay in the know with updates to Johnson & Johnson Press Releases

Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.